Dexterra Group Inc.

Thank you for standing by. This is the conference operator. Welcome to the DxTERRA group's second quarter 2025 results conference call. After the presentation, there will be an opportunity to ask questions. To join the question queue, you may press star, then 1 on your telephone keypad. Should you need assistance during the conference call, you may signal an operator by pressing star, then 0. I would now like to turn the conference over to Denise Achanu, Chief Financial Officer. Please go ahead.

Thank you, Andrea, and good morning. My name is Denise Achanu, Chief Financial Officer of Dextera Group, Inc. With me today on the call are Mark Becker, our CEO, and our Board Chair, Bill McFarland, who will provide some brief introductory comments. After a brief presentation, we will take questions with the call ending by 9.15 Eastern Time. We will be commenting on our Q2 2025 results with the assumption that you have read the Q2 earnings press release MD&A and financial statements. The slide presentation which supports today's comments is posted on our website, and we encourage participants to access the slides and follow along with our presentation. Before we begin, I would like to make some comments about forward-looking information. In yesterday's news release and on slide two of the presentation that we have posted to our website, you will find cautionary notes in that regard. I will not cover the content of the cautionary notes in any detail. However, we do claim their protection for any forward-looking information that we might disclose on this conference call today. I will now turn it over to Bill McFarland for his introductory comment.

Good morning. Thank you, Denise, and thank you to everyone for joining the call. As highlighted in our press release, Q2 was another good quarter for Dextera, and it has been a very active and exciting time for the Dextera team over the past several months, which culminated in the announcement of two strategic investments over the past week. This marks an important milestone for the company and positions Dextera to continue to scale and grow the business in line with our strategy as discussed at the recent annual general meeting. That strategy included growing the US IFM business and making high return investments in our business when accretive opportunities arise. Both of these investments are 100% aligned with that strategy. In line with our focus on delivering shareholder value, I'm pleased to also share that the Board approved an increase in our annual dividend to $0.40 per share. This increase reflects the Board's confidence in the strength and sustainability of the company's business and its robust cash flow generation ability. As you know, we are committed to delivering a return on equity of 15% to shareholders while continuing to build the business for the long term. This includes paying both a meaningful dividend and delivering capital appreciation over time. With that overview, I would now like to pass it over to Mark Becker for more on our recent acquisitions and some comments on the Q2 2025 results.